These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29308322)

  • 1. Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors.
    López-Cobo S; Pieper N; Campos-Silva C; García-Cuesta EM; Reyburn HT; Paschen A; Valés-Gómez M
    Oncoimmunology; 2018; 7(2):e1392426. PubMed ID: 29308322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitor.
    Jazirehi AR; Nazarian R; Torres-Collado AX; Economou JS
    Am J Clin Exp Immunol; 2014; 3(1):43-56. PubMed ID: 24660121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MAPK inhibitors dynamically affect melanoma release of immune NKG2D-ligands, as soluble protein and extracellular vesicle-associated.
    López-Borrego S; Campos-Silva C; Sandúa A; Camino T; Téllez-Pérez L; Alegre E; Beneitez A; Jara-Acevedo R; Paschen A; Pardo M; González Á; Valés-Gómez M
    Front Cell Dev Biol; 2022; 10():1055288. PubMed ID: 36726591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HO-1 downregulation favors BRAF
    Furfaro AL; Ottonello S; Loi G; Cossu I; Piras S; Spagnolo F; Queirolo P; Marinari UM; Moretta L; Pronzato MA; Mingari MC; Pietra G; Nitti M
    Int J Cancer; 2020 Apr; 146(7):1950-1962. PubMed ID: 31376303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.
    Bellmann L; Cappellano G; Schachtl-Riess JF; Prokopi A; Seretis A; Ortner D; Tripp CH; Brinckerhoff CE; Mullins DW; Stoitzner P
    Int J Cancer; 2020 Mar; 146(5):1409-1420. PubMed ID: 31702822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.
    Gallagher SJ; Gunatilake D; Beaumont KA; Sharp DM; Tiffen JC; Heinemann A; Weninger W; Haass NK; Wilmott JS; Madore J; Ferguson PM; Rizos H; Hersey P
    Int J Cancer; 2018 May; 142(9):1926-1937. PubMed ID: 29210065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.
    Ferrari de Andrade L; Ngiow SF; Stannard K; Rusakiewicz S; Kalimutho M; Khanna KK; Tey SK; Takeda K; Zitvogel L; Martinet L; Smyth MJ
    Cancer Res; 2014 Dec; 74(24):7298-308. PubMed ID: 25351955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF Inhibitor Resistance Confers Increased Sensitivity to Mitotic Inhibitors.
    Misek SA; Foda BM; Dexheimer TS; Akram M; Conrad SE; Schmidt JC; Neubig RR; Gallo KA
    Front Oncol; 2022; 12():766794. PubMed ID: 35444937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.
    Chan MM; Haydu LE; Menzies AM; Azer MW; Klein O; Lyle M; Clements A; Guminski A; Kefford RF; Long GV
    Cancer; 2014 Oct; 120(20):3142-53. PubMed ID: 24985732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis.
    Zhang C; Wang Y; Zhou Z; Zhang J; Tian Z
    Cancer Immunol Immunother; 2009 Aug; 58(8):1275-85. PubMed ID: 19139882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiosensitization effect by HDAC inhibition improves NKG2D-dependent natural killer cytotoxicity in hepatocellular carcinoma.
    Liu YF; Chiang Y; Hsu FM; Tsai CL; Cheng JC
    Front Oncol; 2022; 12():1009089. PubMed ID: 36185276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells.
    Atay C; Kwak T; Lavilla-Alonso S; Donthireddy L; Richards A; Moberg V; Pilon-Thomas S; Schell M; Messina JL; Rebecca VW; Xiao M; Tan J; Zhang G; Weber JS; Herlyn M; Sarnaik AA; Gabrilovich DI
    Clin Cancer Res; 2019 May; 25(9):2783-2794. PubMed ID: 30765391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
    Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
    Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma.
    Duggan MC; Stiff AR; Bainazar M; Regan K; Olaverria Salavaggione GN; Maharry S; Blachly JS; Krischak M; Walker CJ; Latchana N; Tridandapani S; de la Chapelle A; Eisfeld AK; Carson WE
    Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9629-9634. PubMed ID: 28827320
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
    Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination Treatment with the BRAF
    Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
    Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas.
    Garandeau D; Noujarède J; Leclerc J; Imbert C; Garcia V; Bats ML; Rambow F; Gilhodes J; Filleron T; Meyer N; Brayer S; Arcucci S; Tartare-Deckert S; Ségui B; Marine JC; Levade T; Bertolotto C; Andrieu-Abadie N
    Mol Cancer Ther; 2019 Feb; 18(2):289-300. PubMed ID: 30482853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca
    Hegedüs L; Padányi R; Molnár J; Pászty K; Varga K; Kenessey I; Sárközy E; Wolf M; Grusch M; Hegyi Z; Homolya L; Aigner C; Garay T; Hegedüs B; Tímár J; Kállay E; Enyedi Á
    Front Oncol; 2017; 7():95. PubMed ID: 28596940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.
    Caporali S; Alvino E; Lacal PM; Levati L; Giurato G; Memoli D; Caprini E; Antonini Cappellini GC; D'Atri S
    Int J Oncol; 2016 Sep; 49(3):1164-74. PubMed ID: 27572607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.